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ABSTRACT
Background: We investigated the efficacy of circulating biomarkers together with 
histological grade and age to predict deep myometrial invasion (dMI) in endometrial 
cancer patients.
Methods: HE4ren was developed adjusting HE4 serum levels towards decreased 
glomerular filtration rate as quantified by the eGFR-EPI formula. Preoperative HE4, 
HE4ren, CA125, age, and grade were evaluated in the context of perioperative depth of 
myometrial invasion in endometrial cancer (EC) patients. Continuous and categorized 
models were developed by binary logistic regression for any-grade and for G1-or-G2 
patients based on single-institution data from 120 EC patients and validated against 
multicentric data from 379 EC patients.
Results: In non-cancer individuals, serum HE4 levels increase log-linearly with 
reduced glomerular filtration of eGFR ≤ 90 ml/min/1.73 m2. HE4ren, adjusting HE4 
serum levels to decreased eGFR, was calculated as follows: HE4ren = exp[ln(HE4) +  
2.182 × (eGFR-90) × 10-2]. Serum HE4 but not HE4ren is correlated with age. Model 
with continuous HE4ren, age, and grade predicted dMI in G1-or-G2 EC patients with 
AUC = 0.833 and AUC = 0.715, respectively, in two validation sets. In a simplified 
categorical model for G1-or-G2 patients, risk factors were determined as grade 2, 
HE4ren ≥ 45 pmol/l, CA125 ≥ 35 U/ml, and age ≥ 60. Cumulation of weighted risk 
factors enabled classification of EC patients to low-risk or high-risk for dMI.
Conclusions: We have introduced the HE4ren formula, adjusting serum HE4 
levels to reduced eGFR that enables quantification of time-dependent changes in HE4 
production and elimination irrespective of age and renal function in women. Utilizing 
www.impactjournals.com/oncotarget/         Oncotarget, 2017, Vol. 8, (No. 64), pp: 108213-108222
                                                     Research Paper
Oncotarget108214www.impactjournals.com/oncotarget
HE4ren improves performance of biomarker-based models for prediction of dMI in 
endometrial cancer patients.
INTRODUCTION
Endometrial cancer (EC) is a malignant tumor 
of endometrial epithelial origin, accounting for 20% to 
30% of malignant diseases of the female reproductive 
system [1]. With early manifestation by abnormal 
vaginal bleeding after menopause, approximately 70% 
of endometrial cancers are diagnosed at early stages 
[2]. Prognosis of early stage endometrial carcinoma is 
relatively good in comparison with other gynecological 
malignancies. However, the remaining 30% of patients 
are diagnosed with endometrial cancer at advanced 
stages. Beside FIGO status, the main prognostic factors 
include: histological type (endometrioid versus clear cell, 
squamous, mucinous, serous or mixed types), grade, level 
of myometrial invasion (MI) and the status of pelvic and 
paraaortal lymphatic nodes.
Based on FIGO criteria, endometrial cancer is 
surgically staged [3] by a procedure that may include 
hysterectomy, bilateral salpingo-oophorectomy, a 
collection of pelvic washings, and a selected pelvic and 
para-aortic lymph node dissection. Owing to potential 
morbidity associated with lymphadenectomy leading 
to symptomatic lymphocysts, lymphedema, deep vein 
thrombosis, neurologic injury, vein injury, and need for 
blood transfusion, the decision regarding lymph node 
dissection should be based on quantification of risk factors 
for nodal metastasis, such as histology of tumor, grade, and 
myometrial invasion ≥ 50% (deep MI, dMI) [4]. The depth 
of myometrial spreading is closely related to lymph node 
invasion and correlates with overall survival of patients 
[5]. Due to the need to plan where to perform the surgical 
procedure (in general gynecological centres versus tertiary 
gyneco-oncology centres), and the surgical procedure 
itself (laparoscopy versus open surgery with respect 
to maximizing clinical benefits), various preoperative 
imaging modalities and histological examinations of 
biopsies are exploited with variable predictive value 
towards dMI [6–8]. While for high-risk patients with 
grade 3 endometrial cancer, lymphadenectomy should be 
recommended [9] the risk stratification for grade 1 or 2 EC 
patients can be done perioperatively based on the depth 
of myometrial invasion [9, 10]. Therefore, the inclusion 
of preoperative levels of peripheral blood-derived 
biomarkers is potentially informative when assessing dMI 
and is highly relevant for the risk prediction and decision 
making process for the upfront assessment of the extent of 
endometrial cancer surgery [11, 12].
CA125 is elevated in both primary and recurrent 
endometrial cancers [13–15] and has been shown to be 
predictive of extrauterine disease [16]. The predictive 
value of CA125 is, however, limited due to its low 
specificity resulting from CA125 elevation in a variety 
of benign conditions [17–20]. Human epididymis 
protein 4 (HE4) was shown to be overexpressed in 
serous and endometrioid epithelial ovarian carcinomas 
and uterine cancers and to a lesser extent in pulmonary, 
breast, gastrointestinal, and urological carcinomas [21] 
and is often detectable in the bloodstream of cancer 
patients including patients with endometrial carcinoma 
[22–25]. Unlike CA125 [26], HE4 is cleared from the 
systemic circulation through glomerular filtration due 
to its small molecular size [27]. Consequently, the 
informative relevance of HE4 is hampered in individuals 
with impaired glomerular functions, with false positive 
levels within the range 500-1000 pmol/l in patients with 
chronic kidney disease (CKD) degree 4-5 [28, 29]. Thus, 
decreased renal function needs to be considered in the 
interpretation of HE4 levels with greater importance 
in endometrial cancer patients, where the elevation of 
serum HE4 is often subtle compared to ovarian cancer 
patients.
The aim of this multicentre international study is to 
evaluate preoperative circulating biomarkers CA125, HE4, 
and HE4ren (HE4 level adjusted to glomerular filtration 
rate), together with histological grade and age in predictive 
models of the depth of myometrial invasion in endometrial 
cancer patients to i) identify cases that would benefit from 
lymphadenectomy and ii) exclude from extensive surgery 
those that would not.
RESULTS
Serum HE4 levels are increased by impaired 
renal function: calculation of HE4ren by 
adjusting serum HE4 to eGFR
Serum HE4 levels were measured in a pool of 
gynecologically and oncologically healthy controls 
with normal or reduced kidney function as assessed 
by creatinine-based eGFR. In the range of eGFR ≤ 
90 ml/min/1.73 m2, serum HE4 levels increased log-
linearly (Figure 1 left). To adjust HE4 serum levels to 
decreased eGFR, a HE4ren was calculated as follows: 
HE4ren = exp[ln(HE4) + 2.182 × (eGFR-90) × 10-2] for 
the range eGFR ≤ 90 ml/ min/1.73 m2 ; HE4ren is equal 
to HE4 for the range eGFR > 90 ml/min/1.73 m2 (Figure 
1 right). While HE4 is falsely elevated in individuals with 
impaired glomerular functions, the 95th percentile of the 
HE4ren distribution in the CKD-positive control cohort 
corresponded to 46.6 pmol/l (Supplementary Figure 1).
To address the issue of HE4 age-dependence, 
HE4 and HE4ren were evaluated in the context of age 
in controls, with results showing that serum HE4 was 
correlated with age (Spearman correlation coefficient 
0.637, p < 0.0001) (Figure 2 left). Applying HE4ren, 
Oncotarget108215www.impactjournals.com/oncotarget
the age-dependence was obviated (Spearman correlation 
coefficient 0.210, p = 0.0910) (Figure 2 right). Moreover, 
unlike HE4, HE4ren was independent of menopausal 
status in control group (Supplementary Figure 2).
HE4ren improves the value of preoperative 
prediction of deep myometrial invasion in 
endometrial cancer patients
HE4ren was calculated for all patients in training 
and validation sets (Supplementary Table 1) and further 
evaluated together with other variables (CA125, grade, 
and age) to predict the dMI in EC patients. Univariable 
analysis of the predictive value of age, grade, CA125, 
HE4, and HE4ren was performed for 3 pools of patients 
(MMCI training, MMCI validation, ENDOMET 
validation) (Supplementary Table 2). As preoperative 
grade 3 endometrial cancer patients are managed as a 
high-risk group with open surgery, the univariable analysis 
was performed separately for the cohort of grade 1 plus 
grade 2 (G1-or-G2) patients (Supplementary Table 2).
Univariable analysis of the MMCI training set 
revealed that the following parameters are predictive 
of dMI: age, CA125, HE4 and HE4ren with best 
discriminative value achieved by HE4 with an AUC 
= 0.7951 for the any-grade pool of patients and AUC 
= 0.7912 for the grade 1-or-2 subcohort. In contrast, 
histological grade was not a statistically significant 
predictor of dMI (Supplementary Table 2).
Continuous model development and validation
Four models based on continuous variables (age, 
CA125, grade, and HE4 or HE4ren) were developed by 
binary logistic regression on the training dataset (Table 
1, Supplementary Table 3). In models for the any-grade 
Figure 1: Relationship between HE4 measurements and eGFR.  Left panel: Association between serum HE4 level (pmol/l) and 
eGFR (ml/min/1.73 m2). Right panel: HE4ren was calculated to quantify serum HE4 in the range of decreased eGFR.
Figure 2: Relationship between HE4 measurements and age.  Left panel: Association between serum HE4 level (pmol/l) and age. 
Right panel: HE4ren is age-independent.
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cohort, grade and preoperative serum CA125 levels 
appeared to be insignificant predictors of dMI. Both HE4 
and HE4ren were stronger predictors of dMI than age. In 
models for the G1-or-G2 subcohort, age, grade (G1 versus 
G2) and HE4 concentrations appeared to be significant 
predictors of dMI with HE4ren having the strongest 
predictive value (Table 1). In both validation sets, for the 
any-grade and G1-or-G2 subcohorts, the predictive value 
of models with continuous variables for dMI was higher 
for HE4ren-based models compared to HE4-based models.
Application of the HE4ren-based final model on 
the G1-or-G2 MMCI validation set and ENDOMET 
validation set revealed an AUC = 0.8333 for MMCI 
validation set and AUC = 0.7146 for the ENDOMET 
validation set (Table 1). In the G1-or-G2 subcohort, the 
HE4ren-based model provided an improvement in dMI 
prediction compared to the HE4-based model in both the 
training set and the ENDOMET validation set (Figure 3).
The predictive values of the respective models in the 
training set and validation sets were calculated for various 
Table 1: Multivariable analysis of dMI prediction with continuous variables 
Model Predictor AUC
Age HE4 HE4ren Grade CA125 MMCI 
training
MMCI 
validation
ENDOMET 
validation
Any grade
Continuous-
all-HE4
OR: 1.06 (1.01-1.13)
p = 0.0355
OR: 5.80 (2.48-16.1)
p = 0.0002
NS NS 0.8045 0.7546 0.7043
Continuous-
all-HE4ren
OR: 1.09 (1.04-1.16)
p = 0.0020
OR: 6.66 (2.86-18.5)
p < 0.0001 NS NS 0.8221 0.7546 0.7125
G1-or-G2
Continuous-
G1/2-HE4
OR: 1.07 (1.00-1.14)
p = 0.0587
OR: 4.84 (1.98-15.3)
p = 0.0026
OR: 2.32 (0.89-6.33)
p = 0.0899
NS 0.8162 0.7955 0.7043
Continuous-
G1/2-HE4ren
OR: 1.10 (1.03-1.18)
p = 0.0051
OR: 8.08 (2.88-30.1)
p = 0.0005
OR: 2.38 (0.88-6.74)
p = 0.0913 NS 0.8373 0.8333 0.7146
P dMI
e age HE ren grade
( ) . . . log . ( )= + − − − −
1
1 15 2 0 1 2 1 4 0 9 1
NS = not significant. Biomarker values were log (ln) transformed. The final model with real-life clinical applicability is shown 
in bold with detailed description of the model where P(dMI) stands for the probability of having myometrial invasion ≥ 50%.
Figure 3: ROC curves of computational models with continuous variables.
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cut-off values of dMI probability (Supplementary Table 
4). Optimal cut-off value of probability of dMI derived 
from the training dataset was 43% with sensitivity 78.9%, 
specificity 85.0%, positive predictive value 76.9% and 
negative predictive value 86.4%. This cut-off value of 
43% yielded the most effective analytical parameters for 
both validation datasets: MMCI validation with sensitivity 
66.7%, specificity 86.4%, positive predictive value 
57.1% and negative predictive value 90.5%; ENDOMET 
validation with sensitivity 59.8%, specificity 70.5%, 
positive predictive value 52.7% and negative predictive 
value 76.1% (Supplementary Table 4).
Categorical model development and validation
Models for categorical variables based on age, 
HE4ren, CA125, and grade were developed for any-grade 
conditions and G1-or-G2 conditions. In any-grade EC 
patients, age, HE4ren, and CA125 but not grade were 
significant predictors of dMI. In G1-or-G2 EC patients, 
all variables were predictors of dMI in this order of 
significance: HE4ren, age, CA125, histological grade 
(Supplementary Table 5). AUC values for training and 
validation datasets are shown in Supplementary Table 5.
For G1-or-G2 EC patients, specific score values 
for each categorical variable and total score for 
various levels of probability of dMI were calculated 
(Supplementary Table 5). The predictive value of the 
model in training set and validation sets were calculated 
for various cut-off values of dMI (Supplementary 
Table 6). With respect to highest sum of specificity 
and sensitivity, the optimal cut-off value derived 
from the training dataset was 33% (Supplementary 
Table 6). Testing these cut-off values in validation 
sets while favouring sensitivity, we observed the most 
effective analytical parameters for the 25% cut-off 
for both validation datasets: MMCI validation with 
positive predictive value 44.4% and negative predictive 
value 89.5%; ENDOMET validation with positive 
predictive value 51.4% and negative predictive value 
82.7% (Supplementary Table 6). Twenty-five percent 
probability of having dMI was set as a cut-off between 
the “low-risk” and the “high-risk” groups of patients and 
enabled simplification of the model in the following way. 
A probability of dMI equal to 25% corresponded to total 
score 27.1. Grade was considered a “minor risk factor” 
with a simplified score value of 1, increased HE4ren and 
CA125 as an “intermediate risk factor” with simplified 
score value of 2, and age equal to or above 60 years as 
a “major risk factor” with a simplified score value of 
3. A sum of these score values ≤ 3 corresponded to a 
probability less than 25% of having dMI and patients 
were thus classified as low-risk for dMI. A sum of these 
score values ≥ 4 corresponded to a probability above 
25% of having dMI and patients were classified as high-
risk for dMI (Supplementary Table 5). An algorithm tree 
for simplified dMI predictive model in G1/2 EC patients 
have been prepared (Supplementary Figure 3).
DISCUSSION
We investigated the efficacy of circulating 
biomarkers to predict deep myometrial invasion in 
endometrial cancer patients. Preoperative stratification of 
the patients to high-risk or low-risk category may guide 
gynecologic oncology surgeons to select the patients 
that would benefit from extensive surgery including 
lymphadenectomy and consequently to plan the surgical 
procedure to the respective center.
Previous studies have shown that HE4 is a useful 
biomarker for stratifying endometrial cancer patients 
according to extent of disease [11, 30–34]. However, 
serum biomarker HE4 generally suffers from low 
specificity as shown by its accumulation in blood in 
patients with reduced glomerular functions [29, 35, 36]. 
Subsequently, there is no generally accepted cut-off 
value of HE4 for its primary clinical application in the 
diagnosis of ovarian cancer [36, 37]. In this study, we 
show that being elevated in subclinically reduced eGFR 
lower than 90 ml/min/1.73 m2, HE4 serum levels are 
highly sensitive to impaired glomerular filtration. eGFR-
dependent levels of serum HE4 enabled us to develop the 
HE4ren formula that is suitable for quantifying serum HE4 
concentrations in women with impaired renal function. 
Furthermore, here we show that HE4ren is independent 
of age and menopausal status suggesting that previously 
described age-associated decrease in glomerular filtration 
is an underlying factor for elevated serum HE4 levels 
in postmenopausal elderly women [36, 38, 39]. The 95th 
percentile of HE4ren levels in control CKD-positive 
individuals corresponds to 46.6 pmol/l, suggesting that 
a cut-off value for HE4ren would be approximately 50 
pmol/l irrespective of age. It is of note that these data and 
subsequent models are derived from Abbott-based serum 
HE4 and CA125 concentrations and eGFR based on a 
CKD-EPI equation employing creatinine quantified by 
enzymatic method. Unlike HE4 that is consistently and 
substantially higher in Li-heparin plasma compared to 
serum (data not shown), serum and plasma yields equal 
concentrations of creatinine and CA125. Therefore if 
single one blood specimen is preferred for the biomarker-
based predictive evaluation of dMI in EC patients 
suggested here, all measurements should be performed 
from serum.
Reflecting the issue of CKD-induced increase 
of serum HE4 levels, Kappelmayer et al. proposed an 
algorithm for the prediction of ovarian cancer that uses 
eGFR, serum HE4, and CA125 levels - regardless of the 
menopause status - in patients who suffer from kidney 
disorders [35]. Compared to this algorithm, HE4ren 
provides the capability of longitudinal quantification of 
HE4 release to serum in conditions of varying severity 
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of kidney impairment. Therefore, at MMCI, HE4ren is 
calculated and reported together with direct serum HE4 
and CA125 concentrations to aid oncogynecologists in the 
management of the diagnostic process and the follow-up of 
ovarian cancer patients with CKD. The reporting of HE4 
serum concentrations in the form of HE4ren during follow-
up of ovarian cancer patients may augment the clinical 
validity of this biomarker as it takes into consideration 
invariable alteration of renal function due to nephrotoxic 
platinum-based treatment in ovarian cancer management. 
It remains to be investigated whether adjustment of HE4 
to kidney insufficiency improves the predictive value of 
indexes that have been established to triage patients with 
suspected epithelial ovarian malignancies [40, 41].
In the evaluation of the continuous parameters 
HE4, CA125, HE4ren, age and grade in the preoperative 
prediction of dMI in endometrial cancer patients, direct 
HE4 has shown the strongest predictive power in the 
univariable analysis due to its dependence on age that 
is itself a strong predictor of dMI. On the other hand, 
Table 2: Characteristics of EC patients 
MMCI training MMCI validation ENDOMET validation
Any grade G1-or-G2 Any grade G1-or-G2 Any grade G1-or-G2
No. of patients 120 98 33 28 346 273
Age
years 65 (60-72) 65 (60-71) 61 (53-73) 62 (52-72) 65 (59-74) 65 (58-73)
< 60 27 (22.5) 24 (24.5) 16 (48.5) 13 (46.4) 102 (29.5) 83 (30.4)
≥ 60 93 (77.5) 74 (75.5) 17 (51.5) 15 (53.6) 244 (70.5) 190 (69.6)
FIGO stage
AEH 17 (4.9) 0 (0.0)
IA 60 (50.0) 55 (56.1) 22 (66.7) 20 (71.4) 197 (56.9) 174 (63.7)
IB 28 (23.3) 22 (22.4) 8 (24.3) 6 (21.4) 39 (11.3) 35 (12.8)
II 21 (17.5) 14 (14.2) 1 (3.0) 1 (3.6) 40 (11.7) 35 (12.8)
IIIA 1 (0.8) 0 (0.0) 1 (3.0) 0 (0.0) 18 (5.2) 12 (4.4)
IIIB 2 (1.7) 1 (1.0) 4 (1.2) 3 (1.1)
IIIC 7 (5.8) 5 (5.1) 25 (7.2) 14 (5.1)
IVA 0 (0.0) 0 (0.0) 2 (0.6) 0 (0.0)
IVB 1 (0.8) 1 (1.0) 4 (1.2) 0 (0.0)
TIS 1 (3.0) 1 (3.6)
Myometrial 
invasion
< 50% 69 (57.5) 60 (61.2) 24 (72.7) 22 (78.6) 219 (63.2) 176 (64.5)
≥ 50% (dMI) 51 (42.5) 38 (38.8) 9 (27.3) 6 (21.4) 127 (36.7) 97 (35.5)
Grade
1 54 (45.0) 54 (55.1) 16 (48.5) 16 (57.1) 207 (59.8) 207 (75.8)
2 44 (36.7) 44 (44.9) 12 (36.4) 12 (42.9) 66 (19.1) 66 (24.2)
3 20 (16.7) 5 (15.2) 25 (7.2)
Not grade 2 (1.7) 48 (13.9)
creatinine µmol/l 67 (59-78) 67 (59-80) 67 (55-85) 72 (61-89) 65 (58-72) 65 (58-72)
eGFR ml/min/1.73 m2 84 (66-90) 84 (60-90) 90 (66-90) 84 (66-90) 84 (72-96) 84 (72-96)
HE4 pmol/l 62.6  
(43.7-93.7)
60.5  
(42.2-85.2)
52.3  
(35.0-74.5)
43.6  
(34.7-77.1)
60.7  
(41.0-104.4)
60.4  
(41.5-94.2)
CA125
U/ml
17.7  
(12.0-30.2)
16.8  
(11.6-30.0)
16.1  
(11.7-21.4)
15.9  
(11.5-20.4)
17.1  
(9.5-28.1)
16.0  
(9.3-25.6)
< 35 97 (80.8) 81 (82.7) 29 (87.9) 26 (92.9) 282 (81.5) 230 (84.2)
≥ 35 23 (19.2) 17 (17.3) 4 (12.1) 2 (7.1) 64 (18.5) 43 (15.8)
For categorical parameters, absolute numbers and percentage are shown in brackets. For continuous parameters, median and 
interquartile range are presented in brackets.
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age-dependence is eliminated in HE4ren. Testing 
models based on continuous variables to predict dMI, 
models with HE4ren yielded better analytical value 
for both any-grade patients and grade 1-or-2 patients 
compared to models with crude serum HE4 levels. As 
grade 3 endometrial cancer patients are considered and 
subsequently managed as high-risk, our final predictive 
models were set for grade 1-or-2 EC patients. We present 
the model based on continuous age, HE4ren and grade, 
calculating the probability of dMI in EC patients. A final 
simplified model with categorical variables based on the 
variables HE4ren, age, CA125, and grade, in this order of 
significance, was able to predict dMI with sensitivity of 
90% and specificity of 57% in the training set. Applying a 
simplified categorical model on both validation datasets, 
the sensitivity was 67% and the specificity was 77% for 
the MMCI validation dataset and 60% sensitivity and 83% 
specificity was observed for the ENDOMET validation 
dataset. Applying newly developed HE4ren-based models 
on variables retrieved from the Danish ENDOMET project 
and their comparison with the original predictive model 
based on HE4 and CA125 in the ENDOMET study [11] 
revealed improvement in analytical values. Unlike for 
MMCI patients, elevated serum CA125 was a strong 
predictor of dMI in the ENDOMET validation dataset 
and thus the simplified categorical model yielded better 
analytical performance in the ENDOMET dataset than the 
continuous model due to an inclusion of CA125 into the 
categorical model.
In conclusion, we have introduced HE4ren adjusting 
serum HE4 levels to reduced glomerular filtration in 
women, enabling quantification of the dynamics of 
HE4 production irrespective of age and in conditions 
of impaired glomerular functions. Applying HE4ren 
improves the performance of developed models for 
prediction of dMI in endometrial cancer patients.
MATERIALS AND METHODS
Study design
First, a mathematical formula named “HE4ren” 
was developed with adjustment of HE4 serum levels 
towards decreased glomerular filtration rate in non-cancer 
individuals. Second, preoperative laboratory parameters 
HE4, HE4ren, CA125 and clinical parameters such as 
age and grade were evaluated to predict the preoperative 
risk of the depth of myometrial invasion in endometrial 
cancer patients. Continuous and categorized models were 
established based on single-institution data in the training 
phase and tested on multicentric data in the validation 
phase. The study was approved by Ethical Board of 
Masaryk Memorial Cancer Institute (MMCI; approval No. 
2016/2832/MOU) and by relevant Danish authorities as 
described previously [11].
Patients and study population
The control group for HE4ren development 
consisted of 66 gynecologically and oncologically healthy 
women with various levels of glomerular filtration rate. 
The endometrial cancer population for dMI prediction 
model development consisted of MMCI training cohort 
and validation cohorts. A retrospective training cohort 
was represented by 120 EC patients treated at Masaryk 
Memorial Cancer Institute, Comprehensive Cancer 
Centre in Brno, Czech Republic, between October 2011 
and March 2015. Validation cohorts consisted of 33 EC 
patients treated at MMCI from April 2015 to January 2016 
and 346 EC patients enrolled in the Danish Endometrial 
Cancer Study (ENDOMET) conducted at 3 tertiary 
gynecologic oncology centres, namely Odense University 
Hospital, Rigshospitalet Copenhagen University Hospital 
and Aalborg University Hospital, between September 
2009 and January 2012 [11] (Table 2).
Histological grade was assessed from preoperative 
endometrial curettage specimens and determined 
according to WHO Classification of Tumours of Female 
Reproductive Organs. Hysterectomy specimens were 
evaluated by a dedicated gynecological pathologist 
perioperatively. The uterus external surface was examined 
macroscopically and the uterus dissected from cervix to 
fundus along its longitudinal axis. The myometrium was 
completely cut in parallel sections with the distance of 5 – 
10mm. The deepest macroscopic tumor invasion and the 
corresponding uterus wall thickness were measured. One 
specimen from the deepest invasion site was examined 
perioperatively in frozen sections and histological type, 
grade and the deepest myometrial invasion in the form of 
x/y mm were reported to the operating room.
Laboratory testing
Preoperative blood samples were obtained from 
EC patients within 2 weeks before scheduled surgical 
treatment. For CA125 and HE4 quantification, serum 
was analyzed within 2 hours from specimen sampling 
at MMCI, and aliquoted and stored at –80 °C until 
analysis in ENDOMET samples. CA125 and HE4 serum 
concentrations were measured by chemiluminescence 
microparticle immunoassay using an Architect i2000sr 
(Abbott) analyzer in all participating centers. In-house 
validation of HE4 measurement linearity ≥ 10 pmol/l 
have been performed (data not shown). Creatinine was 
measured in Li-heparin plasma by an enzymatic method 
with IDMS (isotopic dilution mass spectrometry) 
calibration using center-specific technology. Subsequently, 
estimated glomerular filtration rates (eGFR) were 
calculated by CKD-EPI equations based on sex, age and 
creatinine levels without race-adjustment [42].
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Statistical analysis
The relation between HE4 and eGFR was 
expressed using a piecewise linear regression model 
with logarithmically transformed (natural log) HE4 
concentrations. Based on this relationship, a new 
mathematical parameter “HE4ren” was developed. 
Spearman correlation coefficient is presented for the 
association of HE4 or HE4ren with age. The association 
of the considered variables with dMI was assessed by 
the univariable analysis, using the Pearson chi-square 
test and the Fisher exact test for categorical data and 
the Mann-Whitney test for continuous data. Factors 
showing predictive value in the univariable analysis were 
evaluated by the multivariable analysis. A binary logistic 
regression with backward elimination method was used 
to construct a model to assess the probability of having 
dMI. Results are presented by their odds ratios (OR) with 
95% confidence interval (CI). The significance level used 
for a variable to remain in the model was 0.1. Models 
considering continuous variables were developed with 
both log-transformed HE4 and log-transformed HE4ren. 
Continuous parameters were categorized where cut-
offs were determined using ROC analysis. One model 
with continuous parameters and one with categorical 
parameters were selected and evaluated in more detail 
for use in clinical practice. To make the model more user-
friendly, a score number was assigned to each parameter 
as the corresponding coefficient from the multivariable 
regression model multiplied by 10. Statistical analyses 
were performed using R version 3.2.4.
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